Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 4 Parkinson's papers of 168 | 0.79 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 11207
Sealed predictions
- ZMIZ1 in dopamine neurons, braak-0.16 (p 0.685) → -0.76 (p 0.016)receipt 11214
Swarm cases
receipt 11214: ZMIZ1 in dopamine neurons, braak
- power
- full sample -0.46 (p 0.054, n 18), 95% CI -0.76 to +0.01. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.49 (p 0.041, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.57 (p 0.014, n 18). not the mix.
- skeptic
- leave-one-out range -0.57 to -0.39, sign flips 0; without severely affected donors -0.46 (p 0.054, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.61 (p 0.0067, n 18) vs -0.46 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZMIZ1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZMIZ1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.10 p 0.722 (needs p < 1.9e-4)
Receipts
loading the receipts